JPMorgan analyst Anupam Rama lowered the firm’s price target on Apellis to $57 from $64 and keeps an Overweight rating on the shares. The analyst updated models in the Smid-cap biotechnology space.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis price target lowered to $64 from $72 at JPMorgan
- Apellis price target raised to $41 from $38 at Wedbush
- Apellis price target raised to $96 from $86 at Baird